Partnerships

Admera Health is dedicated to supporting its partners within the precision medicine community. Our experience includes working with both healthcare providers and Biopharma companies to meet their specific needs.

Contact Us
Partnership_Handshake Partnerships

Institutional Partner Solutions

Reserach_Sequencing2 Partnerships

Research sequencing services in a CAP accredited, CLIA certified, CLEP approved environment

Download Research Catalog
White_Glove_icon-1 Partnerships

White glove solutions for hospitals and clinical laboratories

Distribution_Icon1 Partnerships

Opportunities to expand precision medicine through commercial distribution channels

BioPharma Partners Solutions

Genomic, Transcriptome, Methylomic, and Propriety Aptazyme Analysis

Biomarker
Discovery

Retrospective and prospective analysis for patient stratification

Including emerging
immuno-oncology indicators

Companion Diagnostic
Development(CDx)

Analysis of archived samples for molecular subtying

Clinical Trials and Drug Target
Identification

Sequencing to help our partners develop drugs that improve health outcomes

BioPharma Partners Solutions

Genomic, Transcriptome, Methylomic, and Propriety Aptazyme Analysis

Biomarker Discovery

Retrospective and prospective analysis for patient stratification

Including emerging
immuno-oncology indicators

Companion Diagnostic
Development(CDx)

Analysis of archived samples for molecular subtying

Clinical Trials and Drug Target
Identification

Sequencing to help our partners develop drugs that improve health outcomes

Case Studies

High Volume with a Rapid Turnaround Time

Client required whole exome sequencing of 1,000 samples including library preparation for metagenomics analysis. Admera Health delivered results within 15 days.

Customization
Solution

Client required RNAseq and whole exome sequencing for analysis of clonal evolution and evolving neoantigens essential for machinery of leukemogenesis.

Aptazyme
Technology

Utilizing proprietary apatazyme technology, Admera Health developed aptazymes responsive to three small molecules. Delivered aptazyme switches enable the development of controllable gene and cell therapy